http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 05 May 2026 16:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Mar+31/26435856.html si-local-file:///var/storage/secattach/20260505/26435856.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Mar+31/26435856.html Tue, 05 May 2026 16:42:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Mar+31/26435856.html si-local-file:///var/storage/secattach/20260505/26435856.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Mar+31/26435856.html Tue, 05 May 2026 16:42:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+May+05/26435729.html si-local-file:///var/storage/secattach/20260505/26435729.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+May+05/26435729.html Tue, 05 May 2026 16:35:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+May+05/26435729.html si-local-file:///var/storage/secattach/20260505/26435729.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+May+05/26435729.html Tue, 05 May 2026 16:35:00 -0400 O.03089849 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html <p align="center">– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –</p> <p align="center">– Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases –</p> <p align="center">– VCN-01 administered to retinoblastoma patients under a compassionate use program, which is expected to provide dosing feasibility and tolerability data for a potential Phase http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+First+Quarter+2026+Operational+Highlights+and+Financial+Results/26435484.html Tue, 05 May 2026 16:30:00 -0400 A.06822034 A.34398696 A.35552990 A.50216777 O.00074346 O.00178204 O.03089849 O.20026344 O.54516537 TOVX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+05/26409402.html si-local-file:///var/storage/secattach/20260430/26409402.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+05/26409402.html Thu, 30 Apr 2026 16:45:00 -0400 O.03089849 TOVX